Literature DB >> 12917764

Trends in incidence and prevalence of specialized intestinal metaplasia, barrett's esophagus, and adenocarcinoma of the gastroesophageal junction.

Manuel Pera1.   

Abstract

Most available information on the epidemiology of Barrettacute;s esophagus (BE) relates to patients with long segments (> 3 cm) of specialized intestinal metaplasia (SIM). Its prevalence is 3% in patients undergoing endoscopy for reflux symptoms and 1% in those undergoing endoscopy for any clinical indication. The latter prevalence is similar to the 1% found in autopsy series. A "silent majority" with BE remain unrecognized in the general population. BE is more common in men, and the prevalence rises with age. Recent endoscopic series document a rise in the diagnosis of endoscopically apparent short segments (< 3 cm) of BE (SSBE). The prevalence of SSBE in both unselected and reflux patients is 8% to 12%. Specialized intestinal metaplasia at the cardia, below a normal-appearing squamocolumnar junction, has been reported to vary from 6% to 25% in patients presenting for upper endoscopy. Unlike patients with long segment Barrett's esophagus (LSBE), the role of gastroesophageal reflux disease in the pathogenesis of SSBE and SIM of the cardia is controversial. Recent data suggest that the etiology of SIM of the cardia might be secondary to Helicobacter pylori infection, although the role of other environmental factors cannot be ruled out. The incidence of adenocarcinoma of the esophagus and esophagogastric juction (EGJ) has been increasing over the past 15 years in Western countries. Surgical series and population-based studies show that by 1994 adenocarcinomas of the esophagus accounted for half of all esophageal cancer among white men. LSBE and SSBE predispose to the development of adenocarcinoma of the esophagus and EGJ. The role of SIM of the cardia as a precursor lesion for EGJ adenocarcinoma is still unclear. The prevalences of dysplasia in LSBE and SSBE are around 6% and 8%, respectively. The incidence of adenocarcinoma in patients with LSBE is about 1 in 100 patient-years. Cancer risk for SSBE and SIM at the cardia is unknown. Smoking and obesity increase the risk for esophageal and EGJ adenocarcinomas.

Entities:  

Mesh:

Year:  2003        PMID: 12917764     DOI: 10.1007/s00268-003-7052-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  77 in total

1.  Assessment of combined bile acid and pH profiles using an automated sampling device in gastro-oesophageal reflux disease.

Authors:  D Nehra; P Howell; J K Pye; J Beynon
Journal:  Br J Surg       Date:  1998-01       Impact factor: 6.939

2.  Continuing climb in rates of esophageal adenocarcinoma: an update.

Authors:  W J Blot; S S Devesa; J F Fraumeni
Journal:  JAMA       Date:  1993-09-15       Impact factor: 56.272

Review 3.  The changing incidence of oesophageal cancer.

Authors:  P I Reed; B J Johnston
Journal:  Endoscopy       Date:  1993-11       Impact factor: 10.093

4.  The extent of Barrett's esophagus depends on the status of the lower esophageal sphincter and the degree of esophageal acid exposure.

Authors:  S Oberg; T R DeMeester; J H Peters; J A Hagen; J J Nigro; S R DeMeester; J Theisen; G M Campos; P F Crookes
Journal:  J Thorac Cardiovasc Surg       Date:  1999-03       Impact factor: 5.209

5.  Adenocarcinoma and Barrett's esophagus. An overrated risk?

Authors:  S J Spechler; A H Robbins; H B Rubins; M E Vincent; T Heeren; W G Doos; T Colton; E M Schimmel
Journal:  Gastroenterology       Date:  1984-10       Impact factor: 22.682

6.  Adenocarcinoma of the esophagogastric junction and Barrett's esophagus.

Authors:  A J Cameron; C T Lomboy; M Pera; H A Carpenter
Journal:  Gastroenterology       Date:  1995-11       Impact factor: 22.682

7.  Clinical, epidemiologic, and morphologic comparison between adenocarcinomas arising in Barrett's esophageal mucosa and in the gastric cardia.

Authors:  R J Kalish; P E Clancy; M B Orringer; H D Appelman
Journal:  Gastroenterology       Date:  1984-03       Impact factor: 22.682

8.  Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus.

Authors:  R C Haggitt; J Tryzelaar; F H Ellis; H Colcher
Journal:  Am J Clin Pathol       Date:  1978-07       Impact factor: 2.493

9.  Barrett's metaplasia and adenocarcinoma of the esophagus and gastroesophageal junction.

Authors:  J J Thompson; K R Zinsser; H T Enterline
Journal:  Hum Pathol       Date:  1983-01       Impact factor: 3.466

10.  Comparative features of esophageal and gastric adenocarcinomas: recent changes in type and frequency.

Authors:  H H Wang; D A Antonioli; H Goldman
Journal:  Hum Pathol       Date:  1986-05       Impact factor: 3.466

View more
  26 in total

1.  The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model.

Authors:  Chung Yin Kong; Kevin J Nattinger; Tristan J Hayeck; Zehra B Omer; Y Claire Wang; Stuart J Spechler; Pamela M McMahon; G Scott Gazelle; Chin Hur
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-19       Impact factor: 4.254

Review 2.  Diagnosis and Management of Functional Heartburn.

Authors:  Christine Hachem; Nicholas J Shaheen
Journal:  Am J Gastroenterol       Date:  2016-01-05       Impact factor: 10.864

3.  Circulating inflammatory cytokines and adipokines are associated with increased risk of Barrett's esophagus: a case-control study.

Authors:  Jose M Garcia; Andres E Splenser; Jennifer Kramer; Abeer Alsarraj; Stephanie Fitzgerald; David Ramsey; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2013-08-15       Impact factor: 11.382

4.  The prevalence of Barrett's esophagus in the US: estimates from a simulation model confirmed by SEER data.

Authors:  T J Hayeck; C Y Kong; S J Spechler; G S Gazelle; C Hur
Journal:  Dis Esophagus       Date:  2010-03-26       Impact factor: 3.429

Review 5.  Barrett esophagus: histology and pathology for the clinician.

Authors:  Robert D Odze
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-07-07       Impact factor: 46.802

6.  Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.

Authors:  Dang M Nguyen; Peter Richardson; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2010-02-23       Impact factor: 22.682

7.  Development, calibration, and validation of a U.S. white male population-based simulation model of esophageal adenocarcinoma.

Authors:  Chin Hur; Tristan J Hayeck; Jennifer M Yeh; Ethan M Richards; Ethan B Richards; Stuart J Spechler; G Scott Gazelle; Chung Yin Kong
Journal:  PLoS One       Date:  2010-03-01       Impact factor: 3.240

8.  Prevalence of dysphagia in patients with gastroesophageal reflux in Germany.

Authors:  Elfriede Bollschweiler; Katharina Knoppe; Eva Wolfgarten; Arnulf H Hölscher
Journal:  Dysphagia       Date:  2008-01-18       Impact factor: 3.438

9.  An orthotopic nude mouse model for preclinical research of gastric cardia cancer.

Authors:  Sarah Bhargava; Birgit Hotz; Heinz J Buhr; Hubert G Hotz
Journal:  Int J Colorectal Dis       Date:  2008-09-30       Impact factor: 2.571

Review 10.  Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies.

Authors:  Yun Hwan Oh; Chan Yoon; Sang Min Park
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.